Roger Jeffs, Liquidia CEO
June 29, 2023 04:01 PM EDT
R&D

Liq­uidia and Unit­ed Ther­a­peu­tics could bring new lung in­di­ca­tion in­to le­gal saga

Katherine Lewin

News Reporter

Liq­uidia said in an SEC fil­ing Wednes­day that it will “ag­gres­sive­ly de­fend” against a po­ten­tial new patent cov­er­ing Unit­ed Ther­a­peu­tics’ tre­pros­tinil …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times